Related Experiment Videos
[Strategy for preventing upper respiratory tract infections. Consensus of the Consulting Committee]
Insights
Early viral respiratory infections in young children can lead to later rhinitis and asthma. This study investigates if loratadine can prevent these conditions by reducing infection severity and frequency in children under 3.
Area of Science:
- Pediatric Allergy and Immunology
- Respiratory Medicine
- Clinical Pharmacology
Background:
- Viral respiratory infections in early childhood are linked to the development of rhinitis and asthma.
- These infections can alter pulmonary and immune system development.
- Loratadine, a second-generation antihistamine, possesses anti-inflammatory properties, making it a potential preventative agent.
Purpose of the Study:
- To evaluate loratadine as a preventative treatment for allergy and asthma in children under 3 years old.
- To assess the efficacy of loratadine in reducing the frequency and severity of upper airway infections.
- To determine the impact of loratadine on infection-related complications and wheezing incidence.
Main Methods:
- A clinical study involving children under 3 years of age.
- Administration of loratadine as a preventative measure.
- Monitoring of upper airway infection rates, severity, complications, and wheezing.
Main Results:
- Data collection is ongoing for the clinical study.
- Preliminary findings on loratadine's preventative effects are not yet available.
- The study aims to establish the value of loratadine in this context.
Conclusions:
- Further research is needed to confirm loratadine's role in preventing childhood allergies and asthma.
- Understanding the long-term effects of early viral infections on respiratory health is crucial.
- Loratadine's anti-inflammatory and anti-histamine properties warrant investigation for preventative pediatric respiratory care.
Abstract:
Epidemiological, biological and clinical studies have shown that viral respiratory infections before the age of 3 years play a crucial role in the later development of rhinitis and asthma. Reduction of their frequency and severity may effect the viral alteration of the pulmonary and immune systems. Because of this, as it combines anti-histamine and anti-inflammatory properties, loratadine, a second generation anti-histamine is a candidate for a study as a preventative treatment for allergy and asthma. A clinical study in children of less than 3 years is in progress to establish the value of this product in reduction of the number and severity of infections of the upper airways, the number of associated complications and the incidence of wheezing.